GSK news via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'GSK news' source. Mon, 06 Feb 2012 01:21:51 +0100 GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020 http://www.medworm.com/index.php?rid=5651578&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2012%2F2012-pressrelease-875381.htm (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5651578 Mon, 30 Jan 2012 10:24:27 +0100 5651578 GSK announces changes to the Board http://www.medworm.com/index.php?rid=5639971&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2012%2F2012-pressrelease-871327.htm GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5639971 Fri, 27 Jan 2012 11:07:11 +0100 5639971 GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina http://www.medworm.com/index.php?rid=5586177&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2012%2F2012-pressrelease-844572.htm (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5586177 Wed, 11 Jan 2012 12:29:01 +0100 5586177 GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma http://www.medworm.com/index.php?rid=5586178&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2012%2F2012-pressrelease-840683.htm GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate “FF”/vilanterol “VI”) in patients with chronic obstructive pulmonary disease (COPD) and of all but one of the pivotal studies in patients with asthma. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5586178 Mon, 09 Jan 2012 07:17:32 +0100 5586178 GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands http://www.medworm.com/index.php?rid=5527943&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-821642.htm In February 2011 GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate annual sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK’s Consumer Healthcare business and allow it to focus on its priority brands and markets. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5527943 Tue, 20 Dec 2011 13:32:07 +0100 5527943 GSK extends pneumococcal vaccine agreement with GAVI Alliance http://www.medworm.com/index.php?rid=5507599&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-815404.htm GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world‟s poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5507599 Fri, 16 Dec 2011 12:10:27 +0100 5507599 GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus http://www.medworm.com/index.php?rid=5507600&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-813312.htm GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trial to evaluate the efficacy, safety and tolerability of BENLYSTA® (belimumab) administered subcutaneously (SC) once-weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5507600 Thu, 15 Dec 2011 12:59:41 +0100 5507600 GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium http://www.medworm.com/index.php?rid=5489229&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-798637.htm Results from TEACH (Tykerb Evaluation After Chemotherapy) were presented today at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5489229 Thu, 08 Dec 2011 22:45:00 +0100 5489229 GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK http://www.medworm.com/index.php?rid=5479025&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-793122.htm GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership will focus on the creation of a specialist 'Wellness Centre' at Tedworth House, a Help for Heroes Personnel Recovery and Assessment Centre located in Wiltshire. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5479025 Wed, 07 Dec 2011 09:14:33 +0100 5479025 GSK statement in response to the Prime Minister’s speech on life sciences http://www.medworm.com/index.php?rid=5479026&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-789508.htm “The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and manufacturing will further strengthen the attractiveness of the UK and most importantly the results of the Innovation Review should ensure that the NHS is a stronger adopter of innovative medicines and technology, ensuring that all patients can benefit from cost-effective treatments and interventions approved by NICE. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5479026 Mon, 05 Dec 2011 14:31:53 +0100 5479026 Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine http://www.medworm.com/index.php?rid=5460725&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-781571.htm GlaxoSmithKline [NYSE:GSK] today submitted additional information to the U.S. Food and Drug Administration (FDA) in support of the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine MenHibrix® (Hib-MenCY-TT). This information was submitted in response to the September 2011 Complete Response letter received from the FDA. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5460725 Thu, 01 Dec 2011 14:15:51 +0100 5460725 Reporting on a core earnings basis will begin with effect from Q1 2012 http://www.medworm.com/index.php?rid=5460726&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-781224.htm As previously announced, GlaxoSmithKline will be introducing core measures for both operating profit and earnings per share to report the performance of the Group with effect from Q1 2012.   (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5460726 Thu, 01 Dec 2011 12:10:59 +0100 5460726 GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries http://www.medworm.com/index.php?rid=5424407&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-747562.htm GlaxoSmithKline today welcomed the decision of the GAVI Board to provide funding to facilitate the provision of cervical cancer immunisation programmes and rubella vaccination, across the world’s poorest countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5424407 Thu, 17 Nov 2011 12:48:09 +0100 5424407 GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development http://www.medworm.com/index.php?rid=5424408&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-745639.htm GlaxoSmithKline (GSK) today welcomes the European Commission’s commitment to promote collaborative research efforts to develop new antibiotics against the growing threat from resistant bacteria. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5424408 Thu, 17 Nov 2011 10:17:00 +0100 5424408 GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes http://www.medworm.com/index.php?rid=5411947&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-742869.htm GlaxoSmithKline (GSK) today announced that topline results have been received from the first of eight Phase III studies of albiglutide to complete in type 2 diabetes. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5411947 Wed, 16 Nov 2011 12:05:59 +0100 5411947 Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types http://www.medworm.com/index.php?rid=5391461&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-723785.htm An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5391461 Wed, 09 Nov 2011 09:16:01 +0100 5391461 GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia http://www.medworm.com/index.php?rid=5391462&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-721916.htm Findings from the ENABLE clinical trials, which evaluated the ability of eltrombopag to raise and maintain platelet levels in patients with chronic hepatitis C virus (HCV) infection and low platelet levels that would preclude initiation of interferon-based antiviral therapy, were presented today at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5391462 Mon, 07 Nov 2011 20:49:58 +0100 5391462 GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government http://www.medworm.com/index.php?rid=5367737&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-710182.htm GSKannounced that it has reached an agreement in principle with the US Government to conclude the Company’s most significant ongoing Federal government investigations, specifically: the investigation into GSK’s sales and marketing practices begun by the US Attorney’s office of Colorado in 2004 and later taken over by the US Attorney’s Office of Massachusetts;  the U.S. Department of Justice’s investigation of possible inappropriate use of the nominal price exception  under the Medicaid Rebate Program;  and the Department of Justice’s investigation of the development and marketing of Avandia. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5367737 Thu, 03 Nov 2011 07:00:00 +0100 5367737 GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3% http://www.medworm.com/index.php?rid=5350690&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-692882.htm (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5350690 Wed, 26 Oct 2011 10:38:58 +0100 5350690 GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world http://www.medworm.com/index.php?rid=5350691&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-692768.htm GlaxoSmithKline (GSK) today announced it has joined WIPO Re:Search as part of its open innovation strategy to help accelerate the development of new and better treatments against neglected tropical diseases (NTDs) which affect more than a billion people in the world’s poorest countries each year. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5350691 Wed, 26 Oct 2011 09:00:00 +0100 5350691 First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months http://www.medworm.com/index.php?rid=5326189&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-676305.htm First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5326189 Tue, 18 Oct 2011 17:00:00 +0100 5326189 Regulatory Update: GlaxoSmithKline receives Complete Response letter from FDA for candidate meningococcal and Hib combination vaccine http://www.medworm.com/index.php?rid=5253358&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-636304.htm GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine, MenHibrix® (Hib-MenCY-TT). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5253358 Fri, 23 Sep 2011 20:52:32 +0100 5253358 Lucozade to help drive Vodafone McLaren Mercedes performance http://www.medworm.com/index.php?rid=5241301&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-633494.htm Ahead of this weekend’s Singapore Grand Prix, Lucozade – the UK’s leading sports and energy drink – today announces an innovative performance partnership with the Vodafone McLaren Mercedes Formula 1 team. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5241301 Thu, 22 Sep 2011 09:35:17 +0100 5241301 GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership http://www.medworm.com/index.php?rid=5229051&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-625498.htm GlaxoSmithKline (GSK) today announced that it has formed a long term strategic partnership with McLaren Group. The partnership, which will run initially until 2016, brings together two UK companies focused on innovation and high-tech research. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5229051 Thu, 15 Sep 2011 07:19:42 +0100 5229051 GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers http://www.medworm.com/index.php?rid=5229052&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-621052.htm GlaxoSmithKline (GSK) today announced that it has committed $1 million in Cervarix® cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years. GSK has also pledged $50,000 to support the program operations. As a result of this donation, more than 10,000 girls and women will have access to vaccination. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5229052 Tue, 13 Sep 2011 14:58:40 +0100 5229052 GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease http://www.medworm.com/index.php?rid=5212896&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-617531.htm GlaxoSmithKline (GSK) and Amicus Therapeutics today announced the first patient has commenced dosing in a Phase III global registration study (Study 012) to compare the safety and efficacy of Amigal™ (migalastat HCl) and enzyme replacement therapy (ERT) for the treatment of Fabry disease. The randomised, open-label, 18-month study will provide longer-term clinical data comparing migalastat HCl to ERT in patients with Fabry disease, a rare inherited lysosomal storage disorder. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5212896 Mon, 12 Sep 2011 11:54:32 +0100 5212896 GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries http://www.medworm.com/index.php?rid=5212897&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-616401.htm GlaxoSmithKline (GSK) today announced progress on its commitment to expand the donation of albendazole to the World Health Organization (WHO) to treat school age children at risk of intestinal worms, known as soil-transmitted helminths (STH). An agreement signed today formalises the pledge made by GSK in October 2010 to provide an additional 400 million tablets of albendazole per year to WHO to enable de-worming of school age children in Africa. Today’s agreement also provides for albendazole donations to be made to STH endemic countries around the world beyond Africa to ensure the greatest possible benefit is derived from this donation. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5212897 Mon, 12 Sep 2011 08:18:47 +0100 5212897 Lapatinib clinical trial update http://www.medworm.com/index.php?rid=5212898&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-614837.htm This study is fully recruited and the remaining three arms of the trial will continue as planned. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5212898 Fri, 09 Sep 2011 11:03:41 +0100 5212898 Jens Eckstein named President of SR One, GSK’s venture healthcare group http://www.medworm.com/index.php?rid=5198716&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-609333.htm Jens Eckstein has been named President of SR One, GSK’s independent healthcare venture organisation, effective 1 October. Jens will report to R&D Chairman Moncef Slaoui and be based in Boston. He replaces Christoph Westphal, who will be leaving GSK at the end of the year to focus on external business interests, including the Longwood Founder’s Fund, in which GSK is an investor. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5198716 Wed, 07 Sep 2011 16:05:35 +0100 5198716 GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games http://www.medworm.com/index.php?rid=5198717&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-588754.htm British Olympic Gold medallist Rebecca Romero today unveiled the biggest 2012 logo on the side of GSK’s headquarters in London. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5198717 Wed, 07 Sep 2011 08:27:00 +0100 5198717 GSK awarded contract by BARDA to support research on potential novel antibiotic http://www.medworm.com/index.php?rid=5198718&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-606905.htm GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5198718 Tue, 06 Sep 2011 21:32:10 +0100 5198718 GSK takes minority stake in new spin out Autifony Therapeutics http://www.medworm.com/index.php?rid=5149525&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-587067.htm GlaxoSmithKline plc today announced that its wholly-owned subsidiary Glaxo Group Limited (GSK) will receive a 25.4% minority equity stake, representing a £1,250,000 investment, in Autifony Therapeutics Limited, a UK-based biotechnology start up created through a funding round of up to £10 million alongside investors Imperial Innovations and SV Life Sciences. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5149525 Mon, 22 Aug 2011 07:30:48 +0100 5149525 GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease http://www.medworm.com/index.php?rid=5127853&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-580727.htm GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone (CLE), in patients with advanced Parkinson’s disease (PD). IPX066 is an extended release capsule formulation of carbidopa-levodopa (CD-LD) under investigation for the treatment of the motor symptoms of PD. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5127853 Mon, 15 Aug 2011 11:23:37 +0100 5127853 GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform http://www.medworm.com/index.php?rid=5112561&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-576592.htm GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed agreements for the supply and commercialisation on an exclusive basis of the Enigma® ML system in Europe and other designated key countries, including India, Brazil and Russia. The agreements include development by Enigma of an initial range of respiratory tests for use on its real-time Polymerase Chain Reaction (PCR) technology platform, and provide GSK the opportunity to generate revenues from further test developments in infectious diseases and in other therapeutic areas relevant to its healthcare business. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5112561 Wed, 10 Aug 2011 13:38:29 +0100 5112561 Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia http://www.medworm.com/index.php?rid=5112562&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-573605.htm GlaxoSmithKline (NYSE and LSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.  The sNDA has been submitted to the FDA by GSK. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5112562 Tue, 09 Aug 2011 20:35:59 +0100 5112562 Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam http://www.medworm.com/index.php?rid=5090423&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-560149.htm Stiefel, a GSK company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12 years of age or older. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5090423 Wed, 03 Aug 2011 13:11:16 +0100 5090423 GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7% http://www.medworm.com/index.php?rid=5065576&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-542439.htm GSK Q2 results 2011 (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5065576 Tue, 26 Jul 2011 09:31:23 +0100 5065576 GlaxoSmithKline European regulatory update on Pandemrix™ http://www.medworm.com/index.php?rid=5043457&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-537971.htm GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to the product label for the H1N1 influenza vaccine, Pandemrix. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5043457 Thu, 21 Jul 2011 15:07:33 +0100 5043457 GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab) http://www.medworm.com/index.php?rid=5032420&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-525094.htm GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorisation for Benlysta® (belimumab) 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5032420 Thu, 14 Jul 2011 10:42:58 +0100 5032420 EU and US Regulatory Update - Votrient® (pazopanib) http://www.medworm.com/index.php?rid=5002118&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-516914.htm GlaxoSmithKline (GSK) announced today that it has submitted a variation to the Marketing Authorisation Application to the European Medicines Agency for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy, or for patients who are unsuited for such therapy.   (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=5002118 Wed, 06 Jul 2011 14:33:41 +0100 5002118 London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport http://www.medworm.com/index.php?rid=4994990&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-515683.htm London 2012 partner GlaxoSmithKline (GSK) today signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4994990 Mon, 04 Jul 2011 13:01:46 +0100 4994990 GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan http://www.medworm.com/index.php?rid=4988327&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-514209.htm GlaxoSmithKline (GSK) today announced that its rotavirus vaccine has received approval in Japan from the Ministry of Health, Labour and Welfare (MHLW) for use in infants to prevent gastroenteritis caused by rotavirus. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4988327 Fri, 01 Jul 2011 12:19:23 +0100 4988327 GSK welcomes external scientists to diseases of the developing world research campus http://www.medworm.com/index.php?rid=4979215&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-508935.htm External researchers from six medical research organisations have begun work in the GlaxoSmithKline (GSK) ‘open lab’ in Spain, as part of GSK’s experiment to stimulate collaboration in the search for new medicines against diseases of the developing world, such as malaria and drug resistant tuberculosis. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4979215 Tue, 28 Jun 2011 11:50:25 +0100 4979215 GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s http://www.medworm.com/index.php?rid=4963703&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-504553.htm Research led by the University of East Anglia has been published in the Journal of the American Geriatrics Society i examining the long term health impacts of anticholinergic medicines, a wide-ranging group of drugs frequently taken by older people. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4963703 Fri, 24 Jun 2011 12:02:13 +0100 4963703 GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility http://www.medworm.com/index.php?rid=4963704&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-503212.htm GlaxoSmithKline (GSK) has agreed to pay $40.75 million, which will be divided among 37 states and the District of Columbia, as part of an agreement reached related to events during the early 2000s at its former manufacturing facility in Cidra, Puerto Rico. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4963704 Thu, 23 Jun 2011 14:49:40 +0100 4963704 GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China http://www.medworm.com/index.php?rid=4925825&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-470377.htm GSK announced that it has entered into an agreement to acquire the remaining 51% equity interest of Neptunus in the JV company, GSKNB, for a total cash consideration of £24 million (US$39 million).  After approval of this agreement by the Peoples Republic of China’s authorities, GSK will become the sole owner of GSKNB.   (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4925825 Tue, 14 Jun 2011 07:25:17 +0100 4925825 GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine) http://www.medworm.com/index.php?rid=4925826&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-468753.htm GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.         (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4925826 Mon, 13 Jun 2011 06:43:53 +0100 4925826 Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance http://www.medworm.com/index.php?rid=4906953&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-462284.htm GSK today announced that it has made a new offer to supply its rotavirus vaccine, RotarixTM, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices. This announcement is part of the company’s efforts to increase access to its medicines and vaccines in the world’s poorest countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4906953 Mon, 06 Jun 2011 09:30:00 +0100 4906953 GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas http://www.medworm.com/index.php?rid=4906954&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-461982.htm Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement in the time to first occurrence of tumour progression or death (progression free survival or PFS) for study patients treated with the multi-tyrosine kinase inhibitor pazopanib, compared to placebo. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4906954 Sat, 04 Jun 2011 12:00:00 +0100 4906954 GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD http://www.medworm.com/index.php?rid=4887972&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-461192.htm (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4887972 Thu, 02 Jun 2011 11:02:18 +0100 4887972 GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries (LDCs) http://www.medworm.com/index.php?rid=4857183&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-436669.htm GlaxoSmithKline (GSK) today announced further progress on its commitment to reinvest 20% of profits made in the Least Developed Countries (LDCs) back into projects that strengthen the healthcare infrastructure in those countries. GSK has formed a new partnership with three leading NGOs to deliver the reinvestments in LDCs: AMREF in East and Southern Africa, CARE International UK in Asia Pacific and Save the Children in West Africa. The shared objective of the investments will be to improve health outcomes by supporting frontline health workers who operate in these countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4857183 Tue, 24 May 2011 08:10:26 +0100 4857183 GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® (belimumab) http://www.medworm.com/index.php?rid=4844551&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-434551.htm GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Benlysta® (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4844551 Fri, 20 May 2011 10:35:37 +0100 4844551 Young people’s health charity steps forward to claim top accolade and £35,000 http://www.medworm.com/index.php?rid=4816275&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-427380.htm Tower Hamlets-based charity, Step Forward, has beaten more than 400 organisations from around the UK to be crowned the overall winner of this year’s GlaxoSmithKline (GSK) IMPACT Awards, run in partnership with health think-tank The King’s Fund. The charity picked up their award and £35,000 prize at a ceremony last night, held at London’s Science Museum. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4816275 Fri, 13 May 2011 11:13:37 +0100 4816275 Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research http://www.medworm.com/index.php?rid=4816276&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-424268.htm GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of £5M from each partner over a three year period. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4816276 Thu, 12 May 2011 00:01:01 +0100 4816276 GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility http://www.medworm.com/index.php?rid=4755963&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-408360.htm . (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4755963 Wed, 27 Apr 2011 10:52:58 +0100 4755963 Regulatory update – GSK and Valeant respond to FDA on ezogabine http://www.medworm.com/index.php?rid=4728280&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-404368.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) submitted on 15 April 2011 the response to the U.S. Food and Drug Administration (FDA) Complete Response letter received on 30 November 2010 for the New Drug Application (NDA) for ezogabine. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4728280 Mon, 18 Apr 2011 12:13:09 +0100 4728280 GSK welcomes key agreement to support global preparedness against pandemic influenza http://www.medworm.com/index.php?rid=4728281&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-404323.htm GlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic. The agreement establishes the principles of an improved process for influenza virus and benefit-sharing between the WHO GISN (Global Influenza Surveillance Network) and industry. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4728281 Mon, 18 Apr 2011 11:29:35 +0100 4728281 Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine http://www.medworm.com/index.php?rid=4716726&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-403684.htm GlaxoSmithKline [NYSE:GSK] today submitted additional information to the U.S. Food and Drug Administration (FDA) in support of the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine, MenHibrix® (Hib-MenCY-TT). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4716726 Fri, 15 Apr 2011 15:41:00 +0100 4716726 GSK European regulatory update on Pandemrix™ http://www.medworm.com/index.php?rid=4716727&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-403553.htm GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the product label for Pandemrix. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4716727 Fri, 15 Apr 2011 11:10:56 +0100 4716727 Regulatory Update - Tyverb® (lapatinib) http://www.medworm.com/index.php?rid=4716728&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-403443.htm GlaxoSmithKline plc (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Tyverb (lapatinib) in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumours over-express HER2 (ErbB2). Tyverb/Tykerb is approved in over 90 countries including the EU, Switzerland, US, Canada, Japan, Australia and countries in South America and Asia. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4716728 Fri, 15 Apr 2011 09:02:56 +0100 4716728 GlaxoSmithKline announces non-core OTC products to be divested http://www.medworm.com/index.php?rid=4711572&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-402902.htm GSK today identified the non-core OTC brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and the emerging markets. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4711572 Thu, 14 Apr 2011 14:15:13 +0100 4711572 Unique research alliance expands collaboration opportunities at state-of-the-art medical imaging centre http://www.medworm.com/index.php?rid=4700362&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-397993.htm The UK research community will soon have access to world-class medical imaging facilities in London with the signing of an agreement today between an alliance of leading London-based universities, the Medical Research Council (MRC) and the pharmaceutical company GlaxoSmithKline (GSK). In a unique partnership, the MRC, Imperial College London, King’s College London and UCL become equal shareholders in a newly created joint venture that assumes responsibility for the facilities and operations at GSK’s Clinical Imaging Centre (CIC). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4700362 Tue, 12 Apr 2011 10:57:56 +0100 4700362 GlaxoSmithKline and XenoPort receive FDA approval for Horizant™ http://www.medworm.com/index.php?rid=4689038&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-392505.htm GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4689038 Wed, 06 Apr 2011 22:58:29 +0100 4689038 GSK publishes payments for research, consulting and advising by US healthcare professionals http://www.medworm.com/index.php?rid=4673031&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-384520.htm GlaxoSmithKline (NYSE:GSK) today published a list of payments made during 2010 for clinical research studies led by U.S. healthcare professionals. Clinical trials are an important step in the lengthy process of discovering and developing new medicines. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4673031 Thu, 31 Mar 2011 13:00:00 +0100 4673031 GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ US patent litigation http://www.medworm.com/index.php?rid=4673032&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-381896.htm GlaxoSmithKline (GSK), which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed today that Pronova BioPharma Norge AS, which owns the patents for Lovaza, has entered into an agreement with Apotex Corp. and Apotex Inc. (collectively “Apotex”), to settle their patent litigation in the United States related to Lovaza. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4673032 Wed, 30 Mar 2011 08:00:00 +0100 4673032 GSK and Valeant receive European authorisation for Trobalt (retigabine) http://www.medworm.com/index.php?rid=4673033&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-381864.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) announced today that the European Commission has granted marketing authorisation for Trobalt™ (retigabine) as an adjunctive (add-on) treatment of partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalisation in adults aged 18 years and above with epilepsy. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4673033 Tue, 29 Mar 2011 16:00:00 +0100 4673033 GSK publishes 2010 Corporate Responsibility Report http://www.medworm.com/index.php?rid=4673034&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011-pressrelease-381836.htm In its Corporate Responsibility Report published today, GlaxoSmithKline (GSK) reiterated its commitment to building its business on strong values and ethical standards.   (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4673034 Mon, 28 Mar 2011 13:00:00 +0100 4673034 GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction http://www.medworm.com/index.php?rid=4624049&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10043.htm GlaxoSmithKline (GSK) announced today that it will no longer pursue global approval (marketing authorisation) for the use of Avodart™ (dutasteride) to reduce the risk of prostate cancer.  The Company will withdraw applications from regulatory review where procedures are ongoing and, in the limited number of countries where dutasteride is already indicated for use in prostate cancer risk reduction, GSK will work with regulatory agencies to remove this indication from the product’s licence and support physicians to communicate appropriately to patients. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4624049 Wed, 23 Mar 2011 14:06:56 +0100 4624049 GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease http://www.medworm.com/index.php?rid=4585414&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10040.htm GSK announced positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4585414 Mon, 14 Mar 2011 20:00:00 +0100 4585414 GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint http://www.medworm.com/index.php?rid=4572401&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10039.htm GlaxoSmithKline (GSK) and Tolerx, Inc. today announced that the Phase III DEFEND-1 study of otelixizumab, an investigational humanised anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4572401 Fri, 11 Mar 2011 14:00:00 +0100 4572401 GlaxoSmithKline plc appoints two Non-Executive Directors to its Board http://www.medworm.com/index.php?rid=4546646&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10037.htm GlaxoSmithKline plc (GSK) announces that Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board of the Company with effect from 1st April 2011. On appointment, they will both become members of GSK’s Audit & Risk Committee.  Ms. Lewent is the former Executive Vice President and Chief Financial Officer of Merck & Co., Inc. and now serves on the boards of three publicly listed companies and Ms. Cartwright is Executive Vice President, Chief Financial Officer of Burberry Group plc. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4546646 Fri, 04 Mar 2011 10:09:19 +0100 4546646 Regulatory update: Nimenrix® (MenACWY vaccine) http://www.medworm.com/index.php?rid=4537773&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10036.htm GlaxoSmithKline (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its candidate conjugate meningitis vaccine, Nimenrix®, for active immunisation against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 and Y. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4537773 Wed, 02 Mar 2011 11:50:00 +0100 4537773 GSK outlines new plan to drive recruitment and attract graduate talent in the UK http://www.medworm.com/index.php?rid=4537774&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10035.htm GlaxoSmithKline (GSK) today outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4537774 Wed, 02 Mar 2011 08:00:00 +0100 4537774 Reward for charities bridging gaps in health care provision http://www.medworm.com/index.php?rid=4534170&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10034.htm Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care.  The charities beat more than 400 entrants to become winners of this year’s GlaxoSmithKline (GSK) IMPACT Awards, run in partnership with The King’s Fund. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4534170 Tue, 01 Mar 2011 14:22:20 +0100 4534170 World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth http://www.medworm.com/index.php?rid=4534171&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10033.htm GlaxoSmithKline Consumer Healthcare, the maker of leading sensitive toothpaste brand Sensodyne®, today announced a breakthrough in dental care with the launch of new Sensodyne Repair & Protect.  The breakthrough formulation, which the company will launch in over 50 European and International markets during 2011, is the first everyday fluoride toothpaste to contain patented NovaMin® technology, which is scientifically proven to repair* sensitive teeth by forming a tooth-like layer over exposed dentine to help continually repair and protect sensitive areas. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4534171 Tue, 01 Mar 2011 11:12:10 +0100 4534171 David Redfern appointed as new Chairman of ViiV Healthcare http://www.medworm.com/index.php?rid=4519275&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10032.htm GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer today announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st April 2011, following the retirement of Julian Heslop.  David will continue to serve as Chief Strategy Officer at GSK, which owns a majority share in ViiV Healthcare.  (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4519275 Fri, 25 Feb 2011 10:13:04 +0100 4519275 First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism http://www.medworm.com/index.php?rid=4461818&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10026.htm GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme.  Kenya is the first African country to receive pneumococcal vaccines through the innovative financing mechanism known as the Advance Market Commitment (AMC), which is designed to bring heavily discounted vaccines to children living in the world’s poorest countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4461818 Fri, 11 Feb 2011 16:10:37 +0100 4461818 GlaxoSmithKline moving to new building at Philadelphia Navy Yard http://www.medworm.com/index.php?rid=4447558&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_us_pressrelease_10011.htm GlaxoSmithKline (NYSE:GSK), a leading worldwide research-based pharmaceutical company, and Liberty Property Trust (NYSE:LRY) today announced that GSK has signed a 15.5-year lease for a new building to be developed by Liberty Property Trust and Synterra Partners. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4447558 Tue, 08 Feb 2011 20:02:50 +0100 4447558 GSK revises US Avandia label to include new restrictions on use http://www.medworm.com/index.php?rid=4443378&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10024.htm GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines. The new label content reflects the US Food and Drug Administration’s review of cardiovascular event data in type 2 diabetes patients treated with Avandia, and follows a meeting of the joint Advisory Committees in July 2010 and a decision in September 2010 by the FDA to restrict access to these medicines. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4443378 Mon, 07 Feb 2011 16:09:21 +0100 4443378 GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet http://www.medworm.com/index.php?rid=4443379&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10023.htm GlaxoSmithKline (GSK)  and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet .  (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4443379 Mon, 07 Feb 2011 11:49:40 +0100 4443379 GSK results announcement for the fourth quarter http://www.medworm.com/index.php?rid=4430546&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011_pressrelease_10021.htm GSK Q4 and full year results announced (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4430546 Thu, 03 Feb 2011 12:00:00 +0100 4430546 GSK announces the sale of its entire shareholding in Quest Diagnostics http://www.medworm.com/index.php?rid=4426189&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011%2F2011_us_pressrelease_10010.htm GlaxoSmithKline plc (“GSK”) announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (“Quest”). The sale comprised a secondary public offering by GSK (the “Offering”) and an accompanying repurchase of shares by Quest (the “Repurchase”). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4426189 Tue, 01 Feb 2011 23:00:00 +0100 4426189 GSK and Actelion discontinue clinical development of almorexant http://www.medworm.com/index.php?rid=4408232&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10019.htm GlaxoSmithKline (GSK) and Actelion Ltd (SIX: ATLN) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4408232 Fri, 28 Jan 2011 07:30:00 +0100 4408232 GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma http://www.medworm.com/index.php?rid=4391228&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10018.htm GlaxoSmithKline (GSK) announced today the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation. The studies will separately assess the efficacy and safety of two investigational agents, GSK2118436 and GSK1120212, to determine their individual ability to stop or slow the progression of skin cancer in patients whose tumours contain a BRAF V600 mutation, which occurs in 50 to 60 percent of melanoma patients.Commencement of these studies confirms previously announced plans to progress these assets into Phase III. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4391228 Mon, 24 Jan 2011 13:06:58 +0100 4391228 Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine) http://www.medworm.com/index.php?rid=4391229&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10017.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™(retigabine) (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4391229 Fri, 21 Jan 2011 11:30:00 +0100 4391229 GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication http://www.medworm.com/index.php?rid=4365767&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10016.htm GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (`968), in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4365767 Wed, 19 Jan 2011 13:09:19 +0100 4365767 GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza http://www.medworm.com/index.php?rid=4365768&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10015.htm GlaxoSmithKline (GSK) announced today that the first patient has received treatment in a pivotal Phase III study of hospitalised patients with influenza which compares intravenous (IV) zanamivir to oral oseltamivir. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4365768 Wed, 19 Jan 2011 09:00:19 +0100 4365768 GlaxoSmithKline announces Q4 2010 legal charge http://www.medworm.com/index.php?rid=4357812&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10014.htm GlaxoSmithKline (GSK) today announces that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1.8 billion). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4357812 Mon, 17 Jan 2011 14:58:30 +0100 4357812 GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease http://www.medworm.com/index.php?rid=4334069&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10013.htm GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced today that the first patient with Crohn’s disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 (‘786), to placebo. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4334069 Wed, 12 Jan 2011 13:00:00 +0100 4334069 GSK phase III study in HER2-positive advanced breast cancer shows an overall survival benefit when Tyk(v)erb is combined with Paclitaxel http://www.medworm.com/index.php?rid=4391230&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011_pressrelease_138370.htm In a blinded, randomized, Phase III study, women with an advanced form of breast cancer achieved a statistically-significant improvement in overall survival when treated with an investigational combination of Tyk(v)erb® (lapatinib) plus paclitaxel, a widely used chemotherapy agent.[i] The results of the Phase III study in HER2-positve metastatic breast cancer were presented during the 33rd annual meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 8 – 12). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4391230 Mon, 10 Jan 2011 19:40:00 +0100 4391230 Avodart reviewed by FDA advisory committee for prostate cancer risk reduction http://www.medworm.com/index.php?rid=4391231&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011_pressrelease_137614.htm GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA). When asked if the dutasteride risk/benefit profile is favorable for reduction in the risk of prostate cancer in this target population, the ODAC voted 14 against, 2 in favor, and 2 abstentions. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4391231 Mon, 10 Jan 2011 00:00:00 +0100 4391231 GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products http://www.medworm.com/index.php?rid=4328254&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2011_pressrelease_10012.htm GlaxoSmithKline (GSK) and DENTSPLY International, a global leader in professional dental products, today announced that they have entered into an agreement to create a portfolio of co-branded oral care products to be used in the dental office by patients suffering from tooth sensitivity, a problem which is estimated to affect 1 in 3 people. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4328254 Fri, 07 Jan 2011 18:58:35 +0100 4328254 GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD http://www.medworm.com/index.php?rid=4430547&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011_pressrelease_10022.htm Relovair™ programme expanded by start of large Phase IIIb COPD outcomes study (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4430547 Thu, 06 Jan 2011 12:00:00 +0100 4430547 GSK phase III study in HER2-positive advanced breast cancer shows an overall survival benefit when Tyk(v)erb is combined with Paclitaxel http://www.medworm.com/index.php?rid=4391232&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2FLibrary%2Fmedia%2Fpressreleases%2F2011_pressrelease_137605.htm In a blinded, randomized, Phase III study, women with an advanced form of breast cancer achieved a statistically-significant improvement in overall survival when treated with an investigational combination of Tyk(v)erb® (lapatinib) plus paclitaxel, a widely used chemotherapy agent. The results of the Phase III study in HER2-positve metastatic breast cancer were presented during the 33rd annual meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 8 – 12). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4391232 Tue, 04 Jan 2011 00:00:00 +0100 4391232 GSK responds to 60 Minutes http://www.medworm.com/index.php?rid=4328255&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2011%2F2010_us_pressrelease_10111.htm GlaxoSmithKline [GSK] issued the following response regarding a 60 Minutes program on January 2 that focused on a manufacturing facility in Puerto Rico which was formerly owned by the company. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4328255 Mon, 03 Jan 2011 02:29:01 +0100 4328255 GlaxoSmithKline and Theravance commence MABA Phase IIb COPD study http://www.medworm.com/index.php?rid=4328256&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10108.htm GlaxoSmithKline (GSK) and Theravance (NASDAQ: THRX) announced today that the first patient has started treatment with an investigational inhaledbifunctional compound GSK961081 (‘081) in a Phase IIb study to evaluate efficacy and safety in patients with moderate to severe chronic obstructive pulmonary disease (COPD). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4328256 Tue, 21 Dec 2010 21:00:23 +0100 4328256 Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills (BIS) http://www.medworm.com/index.php?rid=4261855&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10130.htm The UK Government today announced that Andrew Witty has been appointed as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4261855 Thu, 16 Dec 2010 01:00:00 +0100 4261855 GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition http://www.medworm.com/index.php?rid=4255796&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10128.htm GSK’ and Maxinutrition Group Holdings Limited today announced they have entered into an agreement for GSK to acquire Maxinutrition, a UK company that manufactures protein-enhanced functional nutrition products, from Darwin Private Equity. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4255796 Mon, 13 Dec 2010 11:00:00 +0100 4255796 Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium http://www.medworm.com/index.php?rid=4247540&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10127.htm Topline results were presented today from two Phase III studies examining the effect of Tykerb (lapatinib) in the neo-adjuvant setting of HER2-positive breast cancer.i, ii The combination of lapatinib and trastuzumab, with standard chemotherapy, was compared to standard chemotherapy plus either lapatinib or trastuzumab in a trial called NeoALTTO. In another trial, known as GeparQuinto, lapatinib plus standard chemotherapy was compared to trastuzumab plus standard chemotherapy. The studies were conducted and presented by international cooperative groups, with research being funded in part by GlaxoSmithKline. Data findings from both trials were presented at the 33rd annual meeting of the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held in San Antonio, Texas (8-12 December 2010). (... GSK news news http://www.medworm.com/rss/comments.php?id=4247540 Fri, 10 Dec 2010 15:36:00 +0100 4247540 GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China http://www.medworm.com/index.php?rid=4235351&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10126.htm GSK announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4235351 Tue, 07 Dec 2010 09:00:00 +0100 4235351 GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011 http://www.medworm.com/index.php?rid=4231755&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10104.htm GSK and Human Genome Sciences announced that the US FDA has extended the PDUFA target date for its priority review of the BLA for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from 9 December 2010 to 10 March 2011. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4231755 Fri, 03 Dec 2010 22:00:00 +0100 4231755 Government patent box proposals ‘transform’ UK attractiveness for investment http://www.medworm.com/index.php?rid=4210589&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10124.htm GSK welcomes the publication today of the Government’s proposals to establish a ‘patent box’. The measure is designed to encourage investment in RD and related manufacturing in the UK by introducing a lower rate of corporation tax on profits generated from UK-owned intellectual property. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4210589 Mon, 29 Nov 2010 16:00:00 +0100 4210589 GlaxoSmithKline to increase its shareholding in Theravance http://www.medworm.com/index.php?rid=4210590&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10123.htm GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) (the “Company”) announced today that GSK will increase its shareholding in Theravance through the purchase of Theravance common stock in a private placement. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4210590 Mon, 29 Nov 2010 09:30:00 +0100 4210590 GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia http://www.medworm.com/index.php?rid=4210591&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10122.htm GlaxoSmithKline (GSK) and JSC Binnopharm (Binnopharm) today announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4210591 Fri, 26 Nov 2010 10:30:00 +0100 4210591 New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients http://www.medworm.com/index.php?rid=4165689&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10120.htm Findings from a new study show, compared to placebo, treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic atrial fibrillation (AF) among patients with symptomatic paroxysmal AF or persistent AF who have no evidence of substantial structural heart disease. The study was presented today at the American Heart Association’s Scientific Sessions and also published online in The Journal of the American Medical Association. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4165689 Mon, 15 Nov 2010 14:00:00 +0100 4165689 GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases http://www.medworm.com/index.php?rid=4161026&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10119.htm GlaxoSmithKline and the Oswald Cruz Foundation (Fiocruz) have today announced a unique collaboration to research and develop new and innovative medicines to treat diseases which disproportionately affect people living in the world’s poorest countries. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4161026 Fri, 12 Nov 2010 14:30:00 +0100 4161026 GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease http://www.medworm.com/index.php?rid=4113398&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10118.htm Amicus to receive $60m in upfront license payment and equity investment and eligible for approximately $170M million in future potential milestone payments (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4113398 Fri, 29 Oct 2010 11:30:00 +0100 4113398 GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal http://www.medworm.com/index.php?rid=4113399&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10117.htm GlaxoSmithKline (GSK) announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first new anti-histamine to be made available in Japan for eight years. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4113399 Fri, 29 Oct 2010 11:00:00 +0100 4113399 GSK announces Q3 results for 2010 http://www.medworm.com/index.php?rid=4092553&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10115.htm Q3 EPS before major restructuring of 28.2p. Q3 dividend up 7% to 16p. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4092553 Thu, 21 Oct 2010 11:00:00 +0100 4092553 GSK outlines approach to delivering advances in the treatment of rare diseases http://www.medworm.com/index.php?rid=4079896&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10114.htm GlaxoSmithKline (GSK) today provided further details about the strategic focus and development priorities of the company’s unit dedicated to rare diseases, which was launched in February 2010. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4079896 Mon, 18 Oct 2010 13:00:00 +0100 4079896 GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases http://www.medworm.com/index.php?rid=4075931&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10113.htm GlaxoSmithKline PLC (GSK), Fondazione Telethon and Fondazione San Raffaele today announced a new strategic alliance to research and develop novel treatments to address rare genetic disorders, using gene therapy carried out on stem cells taken from the patient’s bone marrow (ex vivo). The alliance capitalises on research performed at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), a joint venture between Fondazione Telethon and Fondazione San Raffaele established since 1995. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4075931 Mon, 18 Oct 2010 11:00:00 +0100 4075931 GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine http://www.medworm.com/index.php?rid=4070492&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10110.htm At the launch of the World Health Organization’s (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4070492 Thu, 14 Oct 2010 09:00:00 +0100 4070492 GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine) http://www.medworm.com/index.php?rid=4016021&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10105.htm GlaxoSmithKline (GSK) has made the decision not to pursue further worldwide development of Simplirix™ (Herpes Simplex Vaccine), an experimental vaccine intended to prevent genital herpes disease in women. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4016021 Thu, 30 Sep 2010 14:00:00 +0100 4016021 GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® (fondaparinux) http://www.medworm.com/index.php?rid=4008400&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10104.htm GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted an amendment of their marketing authorisation for their anti-clotting agent (antithrombotic) Arixtra® (fondaparinux) in the European Union for a new therapeutic indication. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=4008400 Wed, 29 Sep 2010 09:00:00 +0100 4008400 GSK regulatory update on Avandia following EMA and FDA reviews http://www.medworm.com/index.php?rid=3996375&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10103.htm GSK confirms that following a review of Avandia® by the EMA and the US FDA, each agency has today announced their individual regulatory decisions and the resulting actions. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3996375 Thu, 23 Sep 2010 16:30:00 +0100 3996375 GSK EU regulatory update on Pandemrix™ http://www.medworm.com/index.php?rid=3996376&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fus.gsk.com%2Fhtml%2Fmedia-news%2Fpressreleases%2F2010%2F2010_pressrelease_10102.htm GSK confirmed that on behalf of the EMA, the CHMP has concluded that the available data are insufficient to demonstrate a causal relationship between Pandemrix and the observed cases of narcolepsy. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3996376 Thu, 23 Sep 2010 16:00:00 +0100 3996376 GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme http://www.medworm.com/index.php?rid=3990607&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10101.htm Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential of developmental combination treatment, Relovair, in COPD and asthma (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3990607 Wed, 22 Sep 2010 12:00:00 +0100 3990607 GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications http://www.medworm.com/index.php?rid=3974953&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10098.htm Following the 1st July announcement by GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development programme of ofatumumab in autoimmune indications. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3974953 Thu, 16 Sep 2010 08:00:00 +0100 3974953 GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain http://www.medworm.com/index.php?rid=3963882&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10097.htm The Bone and Joint Decade (BJD) international initiative and GlaxoSmithKline (GSK) today announced the launch of the LIBERATE™ joint pain management programme during the BJD’s World Conference in Lund, Sweden. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3963882 Sat, 11 Sep 2010 10:00:00 +0100 3963882 GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma http://www.medworm.com/index.php?rid=3963883&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10096.htm GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3963883 Wed, 08 Sep 2010 18:00:00 +0100 3963883 GSK announces succession plan for Chief Financial Officer http://www.medworm.com/index.php?rid=3944676&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10094.htm GlaxoSmithKline plc (GSK) today announces that Julian Heslop is to retire as Chief Financial Officer and Executive Director of the company at the end of March 2011. He will be succeeded by Simon Dingemans who is appointed Chief Financial Officer designate and Executive Director effective 4th January 2011. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3944676 Wed, 08 Sep 2010 13:00:00 +0100 3944676 GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio http://www.medworm.com/index.php?rid=3944678&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10092.htm GlaxoSmithKline (GSK) and Lonza today announced that they have entered into a new agreement under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3944678 Wed, 08 Sep 2010 08:00:00 +0100 3944678 Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia http://www.medworm.com/index.php?rid=3944677&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10091.htm Galapagos and GlaxoSmithKline today announced they have reached an agreement for Galapagos to acquire GSK’s state-of-the art research centre in Zagreb, Croatia. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3944677 Wed, 08 Sep 2010 08:00:00 +0100 3944677 BBC Panorama – 6 September 2010: “A Risk Worth Taking?” Programme. GlaxoSmithKline Right of Reply Statement http://www.medworm.com/index.php?rid=3937617&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10090.htm (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3937617 Mon, 06 Sep 2010 19:30:00 +0100 3937617 GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010 http://www.medworm.com/index.php?rid=3937618&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10089.htm GlaxoSmithKline today issued the following statement in anticipation of the BBC Panorama programme, 'A risk worth taking?' which is scheduled to be aired this evening. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3937618 Mon, 06 Sep 2010 10:00:00 +0100 3937618 GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone) http://www.medworm.com/index.php?rid=3937619&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10088.htm GlaxoSmithKline (GSK) continues to work in the best interest of diabetes patients who face this chronic and serious disease. Patients taking Avandia should speak with their doctor about their treatment and any questions they may have regarding their medicine. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3937619 Mon, 06 Sep 2010 00:01:00 +0100 3937619 Reports of narcolepsy in Europe following vaccination with Pandemrix™ http://www.medworm.com/index.php?rid=3931384&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10087.htm GSK initially became aware of possible cases of narcolepsy following vaccination with the adjuvanted H1N1 pandemic vaccine Pandemrix through adverse event reports received by the Swedish Medical Products Agency, and subsequently via media reports in Finland. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3931384 Thu, 02 Sep 2010 17:00:00 +0100 3931384 GSK and Valeant announce new US FDA PDUFA goal date for ezogabine http://www.medworm.com/index.php?rid=3931385&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10072.htm GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3931385 Mon, 30 Aug 2010 18:00:00 +0100 3931385 GSK European Commission amends licence for Cervarix® http://www.medworm.com/index.php?rid=3897926&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10085.htm GlaxoSmithKline (GSK) confirmed today that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3897926 Tue, 24 Aug 2010 10:00:00 +0100 3897926 GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles http://www.medworm.com/index.php?rid=3893962&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10084.htm GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3893962 Mon, 23 Aug 2010 10:00:00 +0100 3893962 GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus http://www.medworm.com/index.php?rid=3883701&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10083.htm GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. The FDA has assigned belimumab a Prescription Drug User Fee Act (PDUFA) target date of 9 December 2010. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3883701 Thu, 19 Aug 2010 11:30:00 +0100 3883701 GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia http://www.medworm.com/index.php?rid=3847274&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10082.htm GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top line results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3847274 Mon, 09 Aug 2010 20:00:00 +0100 3847274 Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance http://www.medworm.com/index.php?rid=3825670&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10080.htm Detailed pictures have been published today showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3825670 Thu, 05 Aug 2010 08:30:00 +0100 3825670 GSK exercises option on Anacor's novel antibiotic for the treatment of gram-negative infections http://www.medworm.com/index.php?rid=3825671&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10081.htm GlaxoSmithKline PLC (GSK) and Anacor Pharmaceuticals today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK '052), formerly known as AN3365. GSK '052 is a novel, systemic antibiotic derived from Anacor's boron chemistry platform. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3825671 Thu, 29 Jul 2010 11:00:00 +0100 3825671 GSK receives CHMP positive opinion for a new indication for Arixtra http://www.medworm.com/index.php?rid=3782620&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10079.htm The first treatment available for superficial vein thrombosis in Europe (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3782620 Fri, 23 Jul 2010 11:30:00 +0100 3782620 GlaxoSmithKline statement in response to FDA announcement on TIDE trial http://www.medworm.com/index.php?rid=3774736&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10078.htm GlaxoSmithKline [NYSE: GSK] confirmed today that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3774736 Wed, 21 Jul 2010 16:15:00 +0100 3774736 GSK announces Q2 2010 results http://www.medworm.com/index.php?rid=3774737&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Finvestors%2Fquarterly_results.htm Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge) (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3774737 Wed, 21 Jul 2010 12:00:00 +0100 3774737 GlaxoSmithKline legal update http://www.medworm.com/index.php?rid=3752397&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10076.htm GlaxoSmithKline (GSK) today announces that it expects to record a legal charge for the second quarter of 2010 of £1.57billion ($2.36 billion) (equating to an after tax cost of £1.35 billion). The charge includes settlements, agreements in principle to settle, and other provisioning for long-standing legal cases. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3752397 Thu, 15 Jul 2010 06:00:00 +0100 3752397 GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone) http://www.medworm.com/index.php?rid=3752398&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10059.htm GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3752398 Wed, 14 Jul 2010 21:15:00 +0100 3752398 GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA http://www.medworm.com/index.php?rid=3748639&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10075.htm . (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3748639 Tue, 13 Jul 2010 14:00:00 +0100 3748639 Data support Avandia (rosiglitazone maleate) cardiovascular safety profile http://www.medworm.com/index.php?rid=3739175&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10074.htm The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate). GSK’s review supports the overall positive benefit-risk profile of rosiglitazone as an important medicine for patients with type 2 diabetes. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3739175 Fri, 09 Jul 2010 13:30:00 +0100 3739175 GSK EU regulatory update on Avandia (rosiglitazone) http://www.medworm.com/index.php?rid=3739176&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10072.htm GlaxoSmithKline (GSK) today confirmed that on behalf of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP) is to review the benefit/risk profile of Avandia (rosiglitazone). (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3739176 Fri, 09 Jul 2010 09:00:00 +0100 3739176 GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore http://www.medworm.com/index.php?rid=3720455&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10071.htm GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB), the government agency responsible for economic growth and development, today jointly awarded funding for eight research projects based in Singapore aimed at growing local capabilities and talent in green and sustainable manufacturing. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3720455 Fri, 02 Jul 2010 11:00:00 +0100 3720455 GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement http://www.medworm.com/index.php?rid=3716742&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10070.htm GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement. (Source: GSK news) GSK news news http://www.medworm.com/rss/comments.php?id=3716742 Thu, 01 Jul 2010 16:00:00 +0100 3716742